Overview

Study to Investigate the Efficacy of a Non-hormonal Drug Against Endometriosis Associated Pelvic Pain

Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
This study was designed as a proof-of-concept trial to evaluate safety, tolerability, and the efficacy of 1800 mg (ZK 811752 600 mg given orally three times daily) over 12 weeks for the treatment of endometriosis associated pelvic pain (EAPP) in comparison to placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Bayer